Vivoryon Therapeutics N.V.
VVY.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | -€0 | €0 | €0 |
| % Growth | 100% | – | -100% | – |
| Cost of Goods Sold | €0 | -€0 | €0 | €0 |
| Gross Profit | -€0 | -€0 | -€0 | €0 |
| % Margin | – | 85.5% | – | 83.9% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | 796.6% | – | -119% |
| Other Income/Exp. Net | €0 | €0 | €0 | €0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | €0 | -€0 | -€0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | 782.9% | – | -117.6% |
| EPS | -0.79 | -1.12 | -1.28 | -0.63 |
| % Growth | 29.5% | 12.5% | -103.2% | – |
| EPS Diluted | -0.79 | -1.12 | -1.28 | -0.63 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | 783.2% | – | -111.8% |